65,437 trials
Hunter Syndrome
Primary: Infusion-Related Adverse Event (IRAE) Rates Between IgG Anti-idursulfase Antibody Positive (Ab+) and Anti-idursulfase IgG Antibody Negative (Ab-) Patients — 0.0121…
Hypertension · Stroke
Primary: The Percentage of Hypertensive Patients Who Achieve Regulated BP Levels According to the ESC/ESH Guidelines, After They Have Been Treated With Eprosartan for 6 Months…
Methicillin-resistant Staphylococcus Aureus
Primary: Main Outcome: Patients With Nosocomial MRSA Clinical Cultures — 0.92; 0.75; 0.63 hazard ratio — p=0.01
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Insomnia
Primary: Number of Participants With an Adverse Event — 235 Participants
Mania · Hypomania · Bipolar Affective Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS) (Montogomery and Asberg, 1979) — 26.20; 20.20; 16.11; 15.22 units on a scale — p=0.05
Postmenopausal Symptoms · Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4 — 12.1; 12.2; 12.6; 12.3 Events per day — p=<0.01
Fragile X Syndrome
Primary: Clinical Global Impression Scale (CGI) — 2.49; 2.97 units on a scale
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet — 9.6; 3.5 units on scale…
HIV Infection
Primary: Percentage of Participants With at Least One Clinical Adverse Experience — 0.0; 42.9 Percentage of participants
Essential Thrombocythemia (ET)
Primary: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months — 12; 14 participants
Axial Spondyloarthritis
Primary: Change From Baseline in Non Steroidal Anti Inflammatory Drug (NSAID) Assessment of the SpondyloArthritis International Society (ASAS) Score at Week 8. — -63.90; -36.63…
Squamous Cell Carcinoma of the Head and Neck Cancer
Primary: Progression-free Survival (PFS) Time: Independent Read Assessments — 1.5; 1.9 months — p=0.793
Cerebral Infarction
Primary: Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE) — 27; 27; 22 Participants
Chemotherapy-Induced Nausea and Vomiting
Primary: Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1 — 54.2; 59.4; 58.6 percentage of patients